13 assets in Progesterone-Receptor Positive Breast Cancer

Therapeutic assets addressing Progesterone-Receptor Positive Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Letrozole Progesterone-Receptor Positive Breast Cancer	Ruth O'Regan	P2	BB (67)
Anastrozole Progesterone-Receptor Positive Breast Cancer	Ruth O'Regan	P2	B (57)
Fulvestrant Progesterone-Receptor Positive Breast Cancer	Massachusetts General Hospital	P2	B (57)
Trastuzumab Progesterone-Receptor Positive Breast Cancer	Massachusetts General Hospital	P2	B (57)
Neratinib Progesterone-Receptor Positive Breast Cancer	Massachusetts General Hospital	P2	CCC (53)
Alpelisib Progesterone-Receptor Positive Breast Cancer	Vanderbilt-Ingram Cancer Center	P1	CC (43)
CD47/SIRPA-BLOCKING AGENT ALX148 Progesterone-Receptor Positive Breast Cancer	QuantumLeap Healthcare Collaborative	P1	CC (43)
Fam-Trastuzumab Deruxtecan-Nxki Progesterone-Receptor Positive Breast Cancer	QuantumLeap Healthcare Collaborative	P1	CC (43)
nkt3447 Progesterone-Receptor Positive Breast Cancer	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Progesterone-Receptor Positive Breast Cancer	NiKang Therapeutics, Inc.	P1	CC (43)
Tucatinib Progesterone-Receptor Positive Breast Cancer	QuantumLeap Healthcare Collaborative	P1	CC (43)
Zanidatamab Progesterone-Receptor Positive Breast Cancer	QuantumLeap Healthcare Collaborative	P1	CC (43)
Brc-001 Progesterone-Receptor Positive Breast Cancer	City of Hope Medical Center	P2	NR ()